Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | BNT111 |
| Synonyms | |
| Therapy Description |
BNT111 is a liposomal RNA vaccine comprising mRNA transcripts that encode wild-type NY-ESO1, MAGE-A3, TYR (aa 1-477), and TPTE tumor specific antigens (TSAs), which is targeted to and expressed in dendritic cells, potentially inducing cytotoxic T-cell response against NY-ESO1, MAGE-A3, TYR, and TPTE expressing tumor cells (PMID: 32728218). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| BNT111 | BNT-111|BNT 111 | BNT111 is a liposomal RNA vaccine comprising mRNA transcripts that encode wild-type NY-ESO1, MAGE-A3, TYR (aa 1-477), and TPTE tumor specific antigens (TSAs), which is targeted to and expressed in dendritic cells, potentially inducing cytotoxic T-cell response against NY-ESO1, MAGE-A3, TYR, and TPTE expressing tumor cells (PMID: 32728218). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT04526899 | Phase II | Cemiplimab BNT111 BNT111 + Cemiplimab | A Study to Investigate the Novel Agent BNT111 and Cemiplimab in Combination or as Single Agents in Patients With Advanced Melanoma That Has Not Responded to Other Forms of Treatment | Active, not recruiting | USA | POL | ITA | GBR | ESP | DEU | AUS | 0 |